^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | TA99 (TYRP1 inhibitor) |
| Drug Class: | MEK inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1845 - Enhancing the efficacy of antitumor antibodies with immune checkpoint inhibitors and targeted therapy in melanoma
Published date:
03/10/2021
Excerpt:
We next combined TA99 and MEKi to treat B16 melanoma in vivo and observed a synergistic reduction in tumor growth. Treatment of mice bearing YUMM melanoma (BRAF mutant) with TA99/MEKi resulted in the complete elimination of tumors in the majority of animals, and produced durable responses.
